AVE 0.00% 0.2¢ avecho biotechnology limited

what we need., page-5

  1. 34,916 Posts.
    lightbulb Created with Sketch. 480
    Very pertinent post lewis. I believe one of the major drivers for POH business will be because of patent expiry. By offering a new, better delivery method in conjunction with TPM, those who have patnets expiring can lock out the competitior again by exclusively dealing with POH for that drug. Exclusively at a premium of course :-)
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.